Ina Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ina Jung has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Laure Vitte
Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 , Grenoble
3 shared publications - Ekaterina Bourova-Flin
Univ. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), Grenoble, France
3 shared publications - Florent Chuffart
Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences
3 shared publications - Saadi Khochbin
Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences
3 shared publications Eleni Nika
CHU Grenoble Alpes Department of Pathology CS 10217 – 38043 Grenoble cedex 09
2 shared publications- Emmanuelle Jacquet
Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences , 38000 Grenoble
2 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 8 (2) , lqag058
Predicting isocitrate dehydrogenase mutation status in acute myeloid leukemia from gene expression profiles by machine learning
We developed machine-learning models to predict isocitrate dehydrogenase (IDH) mutation status in acute myeloid leukemia (AML) from gene expression profiles and to reconstruct missing IDH annotations across public datasets. Transcriptomic data from 19 cohorts (5844 samples) were harmonized using batch correction, and 1546 samples with known IDH status were used to train a feed-forward neural network and a logistic regression (LR) classifier within a nested cross-validation framework, followed by independent validation in the TCGA-LAML dataset. The LR model showed superior performance, achieving receiver operating characteristic area under the curve $=$ 0.994 $\pm$ 0.007, accuracy $=$ 0.983 $\pm$ 0.006, balanced accuracy $=$ 0.979 $\pm$ 0.005, sensitivity for the IDH-mutant (IDH-MUT) class $=$ 0.972 $\pm$ 0.010, and specificity $=$ 0.986 $\pm$ 0.008, and correctly classified all IDH-MUT cases in the independent cohort. Applying the final model to samples lacking annotations enabled reconstruction of IDH status for 4148 AML cases, expanding the number of molecularly characterized transcriptomes available for downstream analyses. Predicted groups recapitulated known IDH-associated transcriptional signatures, supporting biological validity. This work demonstrates that IDH mutation status can be accurately inferred from transcriptomic data alone and provides a scalable framework to recover missing genomic annotations, thereby enhancing the utility of public AML resources for large-scale biological and translational research.- 27 March 2026
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 8 (2) , lqag058
Open AccessPredicting isocitrate dehydrogenase mutation status in acute myeloid leukemia from gene expression profiles by machine learning
We developed machine-learning models to predict isocitrate dehydrogenase (IDH) mutation status in acute myeloid leukemia (AML) from gene expression profiles and to reconstruct missing IDH annotations across public datasets. Transcriptomic data from 19 cohorts (5844 samples) were harmonized using batch correction, and 1546 samples with known IDH status were used to train a feed-forward neural network and a logistic regression (LR) classifier within a nested cross-validation framework, followed by independent validation in the TCGA-LAML dataset. The LR model showed superior performance, achieving receiver operating characteristic area under the curve $=$ 0.994 $\pm$ 0.007, accuracy $=$ 0.983 $\pm$ 0.006, balanced accuracy $=$ 0.979 $\pm$ 0.005, sensitivity for the IDH-mutant (IDH-MUT) class $=$ 0.972 $\pm$ 0.010, and specificity $=$ 0.986 $\pm$ 0.008, and correctly classified all IDH-MUT cases in the independent cohort. Applying the final model to samples lacking annotations enabled reconstruction of IDH status for 4148 AML cases, expanding the number of molecularly characterized transcriptomes available for downstream analyses. Predicted groups recapitulated known IDH-associated transcriptional signatures, supporting biological validity. This work demonstrates that IDH mutation status can be accurately inferred from transcriptomic data alone and provides a scalable framework to recover missing genomic annotations, thereby enhancing the utility of public AML resources for large-scale biological and translational research. - Open Access
- 2 April 2025
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 7 (2) , zcaf020
Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach
Breast cancer is characterized by genetic and epigenetic deregulations, leading to aberrant expression of tissue-specific genes that are normally silent in healthy breast tissue. Our previous work identified the embryonic stem cell-specific gene DNMT3B, a de novo DNA methyltransferase, as aberrantly activated in breast cancer, correlating with aggressive tumour behaviour and high relapse risk, regardless of molecular subtype. Through integrative bioinformatic analyses of DNA methylation and transcriptomic data, we identified 154 genes downregulated via DNMT3B-driven promoter hypermethylation, many of which are associated with high relapse risk. Notably, the tumour suppressor gene GATA3 emerged as a primary target of functional inactivation through either loss-of-function mutations or DNMT3B-controlled hypermethylation, in a mutually exclusive manner. Both mechanisms of GATA3 inactivation were associated with similar molecular signatures linked to tumour progression, increased malignancy, and poorer prognosis. However, distinct differences were observed, with immune- and inflammation-related genes enriched in GATA3 hypermethylation cases but depleted in mutation-driven silencing. Additionally, our analysis uncovered other potential tumour suppressor genes epigenetically repressed in aggressive breast cancers. These findings underscore a broader role of GATA3 inactivation beyond genetic alterations and suggest therapeutic opportunities to target epigenetically silenced tumour suppressors in aggressive breast tumours.
- 2 April 2025
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 7 (2) , zcaf020
Open AccessDiscovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach
Breast cancer is characterized by genetic and epigenetic deregulations, leading to aberrant expression of tissue-specific genes that are normally silent in healthy breast tissue. Our previous work identified the embryonic stem cell-specific gene DNMT3B, a de novo DNA methyltransferase, as aberrantly activated in breast cancer, correlating with aggressive tumour behaviour and high relapse risk, regardless of molecular subtype. Through integrative bioinformatic analyses of DNA methylation and transcriptomic data, we identified 154 genes downregulated via DNMT3B-driven promoter hypermethylation, many of which are associated with high relapse risk. Notably, the tumour suppressor gene GATA3 emerged as a primary target of functional inactivation through either loss-of-function mutations or DNMT3B-controlled hypermethylation, in a mutually exclusive manner. Both mechanisms of GATA3 inactivation were associated with similar molecular signatures linked to tumour progression, increased malignancy, and poorer prognosis. However, distinct differences were observed, with immune- and inflammation-related genes enriched in GATA3 hypermethylation cases but depleted in mutation-driven silencing. Additionally, our analysis uncovered other potential tumour suppressor genes epigenetically repressed in aggressive breast cancers. These findings underscore a broader role of GATA3 inactivation beyond genetic alterations and suggest therapeutic opportunities to target epigenetically silenced tumour suppressors in aggressive breast tumours.
- Open Access
Discovery of Epigenetically Silenced Tumour Suppressor Genes in Aggressive Breast Cancer Through a Computational Approach
Breast cancer is characterized by genetic and epigenetic deregulations, leading to aberrant expression of tissue-specific genes that are normally silent in healthy breast tissue. Our previous work identified the embryonic stem cell-specific gene DNMT3B , a de novo DNA methyltransferase, as aberrantly activated in breast cancer, correlating with aggressive tumour behaviour and high relapse risk, regardless of molecular subtype. Through integrative bioinformatic analyses of DNA methylation and transcriptomic data, we identified 154 genes downregulated via DNMT3B -driven promoter hypermethylation, many of which are associated with high relapse risk. Notably, the tumour suppressor gene GATA3 emerged as a primary target of functional inactivation through either loss-of-function mutations or DNMT3B -controlled hypermethylation, in a mutually exclusive manner. Both mechanisms of GATA3 inactivation were associated with similar molecular signatures linked to tumour progression, increased malignancy, and poorer prognosis. However, distinct differences were observed, with immune- and inflammation-related genes enriched in GATA3 hypermethylation cases but depleted in mutation-driven silencing. Additionally, our analysis uncovered other potential tumour suppressor genes epigenetically repressed in aggressive breast cancers. These findings underscore a broader role of GATA3 inactivation beyond genetic alterations and suggest therapeutic opportunities to target epigenetically silenced tumour suppressors in aggressive breast tumours.
Open AccessDiscovery of Epigenetically Silenced Tumour Suppressor Genes in Aggressive Breast Cancer Through a Computational Approach
Breast cancer is characterized by genetic and epigenetic deregulations, leading to aberrant expression of tissue-specific genes that are normally silent in healthy breast tissue. Our previous work identified the embryonic stem cell-specific gene DNMT3B , a de novo DNA methyltransferase, as aberrantly activated in breast cancer, correlating with aggressive tumour behaviour and high relapse risk, regardless of molecular subtype. Through integrative bioinformatic analyses of DNA methylation and transcriptomic data, we identified 154 genes downregulated via DNMT3B -driven promoter hypermethylation, many of which are associated with high relapse risk. Notably, the tumour suppressor gene GATA3 emerged as a primary target of functional inactivation through either loss-of-function mutations or DNMT3B -controlled hypermethylation, in a mutually exclusive manner. Both mechanisms of GATA3 inactivation were associated with similar molecular signatures linked to tumour progression, increased malignancy, and poorer prognosis. However, distinct differences were observed, with immune- and inflammation-related genes enriched in GATA3 hypermethylation cases but depleted in mutation-driven silencing. Additionally, our analysis uncovered other potential tumour suppressor genes epigenetically repressed in aggressive breast cancers. These findings underscore a broader role of GATA3 inactivation beyond genetic alterations and suggest therapeutic opportunities to target epigenetically silenced tumour suppressors in aggressive breast tumours.